Gibson has led phase 1-4 clinical trials, and cardiology megatrials of up to 30,000 patients which eventuated in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet and devices that alert patients to a heart attack.
Gibson has been chosen as one of Boston's Top Doctors & U.S. News & World Report also lists Gibson as one of America's top doctors. Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count, the TIMI myocardial perfusion grade).